Front Cover: A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR (ChemMedChem 16/2023)
Μarianna Stampolaki, Anja Hoffmann, Dr. Kumar Tekwani, Kyriakos Georgiou, Dr. Christina Tzitzoglaki, Dr. Chunlong Ma, Dr. Stefan Becker, Patrick Schmerer, Kristin D?ring, Dr. Ioannis Stylianakis, Dr. Andreea L. Turcu, Prof.?Dr. Jun Wang, Prof.?Dr. Santiago Vázquez, Prof.?Dr. Loren B. Andreas, Prof.?Dr. Michaela Schmidtke, Prof.?Dr. Antonios Kolocouris
{"title":"Front Cover: A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR (ChemMedChem 16/2023)","authors":"Μarianna Stampolaki, Anja Hoffmann, Dr. Kumar Tekwani, Kyriakos Georgiou, Dr. Christina Tzitzoglaki, Dr. Chunlong Ma, Dr. Stefan Becker, Patrick Schmerer, Kristin D?ring, Dr. Ioannis Stylianakis, Dr. Andreea L. Turcu, Prof.?Dr. Jun Wang, Prof.?Dr. Santiago Vázquez, Prof.?Dr. Loren B. Andreas, Prof.?Dr. Michaela Schmidtke, Prof.?Dr. Antonios Kolocouris","doi":"10.1002/cmdc.202300429","DOIUrl":null,"url":null,"abstract":"<p><b>The Front Cover</b> illustrates the L26F variant of the M2 protein of influenza A virus which is resistant to the amantadine class of drugs. It shows the combination of two methods (MD simulations and MAS NMR) that reveal the binding of a potent inhibitor of the L26F M2 proton channel, RL208, or compound <b>61</b> in the corresponding research. The ligand RL208 is an isomer of amantadine and is described as a triple blocker of WT, L26F, V27A M2 variants. Cover design by Marianna Stampolaki and Kyriakos Georgiou; image <i>Virus Bacterium Infection</i> by PublicDomainPictures from Pixabay used in accordance with the Pixabay license. More information can be found in the Research Article by Μarianna Stampolaki, Anja Hoffmann, Loren B. Andreas, Michaela Schmidtke, Antonios Kolocouris et al.<figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"18 16","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202300429","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202300429","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The Front Cover illustrates the L26F variant of the M2 protein of influenza A virus which is resistant to the amantadine class of drugs. It shows the combination of two methods (MD simulations and MAS NMR) that reveal the binding of a potent inhibitor of the L26F M2 proton channel, RL208, or compound 61 in the corresponding research. The ligand RL208 is an isomer of amantadine and is described as a triple blocker of WT, L26F, V27A M2 variants. Cover design by Marianna Stampolaki and Kyriakos Georgiou; image Virus Bacterium Infection by PublicDomainPictures from Pixabay used in accordance with the Pixabay license. More information can be found in the Research Article by Μarianna Stampolaki, Anja Hoffmann, Loren B. Andreas, Michaela Schmidtke, Antonios Kolocouris et al.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.